Arbutus Biopharma Corp (ABUS)
2.68
-0.01
(-0.37%)
USD |
NASDAQ |
May 02, 16:00
2.685
0.00 (0.00%)
Pre-Market: 20:00
Arbutus Biopharma Enterprise Value: 356.87M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 356.87M |
| May 01, 2024 | 358.67M |
| April 30, 2024 | 365.87M |
| April 29, 2024 | 374.88M |
| April 26, 2024 | 365.87M |
| April 25, 2024 | 364.07M |
| April 24, 2024 | 369.48M |
| April 23, 2024 | 369.48M |
| April 22, 2024 | 349.66M |
| April 19, 2024 | 364.07M |
| April 18, 2024 | 365.87M |
| April 17, 2024 | 374.88M |
| April 16, 2024 | 400.11M |
| April 15, 2024 | 409.12M |
| April 12, 2024 | 398.31M |
| April 11, 2024 | 419.93M |
| April 10, 2024 | 410.92M |
| April 09, 2024 | 415.42M |
| April 08, 2024 | 430.74M |
| April 05, 2024 | 436.14M |
| April 04, 2024 | 414.52M |
| April 03, 2024 | 400.11M |
| April 02, 2024 | 328.04M |
| April 01, 2024 | 335.24M |
| March 28, 2024 | 338.85M |
| Date | Value |
|---|---|
| March 27, 2024 | 342.45M |
| March 26, 2024 | 322.63M |
| March 25, 2024 | 322.63M |
| March 22, 2024 | 322.73M |
| March 21, 2024 | 331.70M |
| March 20, 2024 | 331.70M |
| March 19, 2024 | 322.73M |
| March 18, 2024 | 329.91M |
| March 15, 2024 | 344.27M |
| March 14, 2024 | 342.47M |
| March 13, 2024 | 358.63M |
| March 12, 2024 | 356.83M |
| March 11, 2024 | 362.22M |
| March 08, 2024 | 364.01M |
| March 07, 2024 | 358.63M |
| March 06, 2024 | 365.81M |
| March 05, 2024 | 353.24M |
| March 04, 2024 | 360.42M |
| March 01, 2024 | 374.78M |
| February 29, 2024 | 349.63M |
| February 28, 2024 | 363.22M |
| February 27, 2024 | 370.01M |
| February 26, 2024 | 370.01M |
| February 23, 2024 | 370.01M |
| February 22, 2024 | 368.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
93.78M
Minimum
Oct 09 2019
668.53M
Maximum
Dec 01 2021
272.33M
Average
266.61M
Median
Dec 26 2023
Enterprise Value Benchmarks
| Moderna Inc | 39.50B |
| Pacira BioSciences Inc | 1.514B |
| Chimerix Inc | -97.08M |
| Karyopharm Therapeutics Inc | 104.90M |
| Corvus Pharmaceuticals Inc | 57.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.31M |
| Revenue (Quarterly) | 2.145M |
| Total Expenses (Quarterly) | 22.66M |
| EPS Diluted (Quarterly) | -0.12 |
| Profit Margin (Quarterly) | -900.3% |
| Earnings Yield | -16.42% |
| Normalized Earnings Yield | -16.41 |